MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.drugalcdep.2022.109707

Медицинская библиотека · Drug and alcohol dependence · 2022

The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.

Morford Kenneth L, Tetrault Jeanette M, Zhou Bin, Li Fangyong, Gleeson Brynna, Edelman E Jennifer, Stein Michael D, Barry Declan T, Madden Lynn

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Open-access opioid treatment programs (OTP) offer same-day access to methadone without an appointment and aim to minimize treatment barriers that often reduce admission and/or retention. We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.

METHODS

We conducted a retrospective cohort study of 2968 patients consecutively initiated on methadone between January 2015 and February 2017 at an open-access OTP. The sample was stratified into benzodiazepine-exposed and nonexposed groups based on intake urine toxicology. Group comparison of 12-month retention was conducted. Kaplan Meier analysis compared time to methadone treatment discontinuation between groups with a log-rank test. Multivariable Cox regression was performed to compare retention by baseline benzodiazepine exposure with adjustment for confounders.

RESULTS

Overall, 31% of patients with benzodiazepine exposure (n = 171) and 31% without exposure (n = 2423) were retained at 12 months (p = 0.95). Median treatment duration was 182 days (95% CI, 152-239) and 175 days (95% CI, 156-196) for patients with and without benzodiazepine exposure, respectively. Kaplan-Meier analysis showed no significant difference in treatment duration between groups (log-rank test p = 0.73). Cox regression found no difference in treatment retention between groups (adjusted Hazard Ratio= 1.03, 95% CI, 0.91-1.16).

CONCLUSIONS

In this cohort of patients receiving methadone at an open-access OTP, benzodiazepine exposure at intake was not observed to impact 12-month treatment retention or duration. These findings support U.S. Food and Drug Administration (FDA) recommendations to not withhold medications for opioid use disorder from patients taking benzodiazepines.

Для цитирования: Morford Kenneth L, Tetrault Jeanette M, Zhou Bin, Li Fangyong, Gleeson Brynna, Edelman E Jennifer, Stein Michael D, Barry Declan T, Madden Lynn. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.. Drug and alcohol dependence. 2022. DOI: 10.1016/j.drugalcdep.2022.109707.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.